REGN - Regeneron Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

REGN is currently covered by 32 analysts with an average price target of $1146.76. This is a potential upside of $107.65 (10.36%) from yesterday's end of day stock price of $1039.11.

Regeneron Pharmaceuticals's activity chart (see below) currently has 500 price targets and 552 ratings on display. The stock rating distribution of REGN is 36.09% HOLD, 62.41% BUY and 1.5% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 93.99% with an average time for these price targets to be met of 262.56 days.

Highest price target for REGN is $1229, Lowest price target is $720, average price target is $1146.76.

Most recent stock forecast was given by CHRIS SCHOTT from JPMORGAN on 17-Jun-2024. First documented stock forecast 27-Feb-2009.


Regeneron Pharmaceuticals specializes in  products that enable minimally invasive care.


The da Vinci Surgical System is a robotic surgical system that includes:

  • A console where the surgeon sits and controls the instruments and a high-definition 3D camera.

The surgeon uses the console to control the instruments, which are inserted into the patient’s body through small incisions. The system allows for greater precision and control during surgery, resulting in reduced trauma to the patient and faster recovery times.

The Ion endoluminal system enables minimally invasive biopsies in the lung, which can help diagnose lung cancer and other conditions.

Intuitive Surgical also provides a suite of stapling, energy, and core instrumentation for its surgical systems, as well as progressive learning pathways to support the use of its technology. The company offers a complement of services to its customers, including support, installation, repair, and maintenance, to ensure that its products operate efficiently and effectively.

Moreover, Intuitive Surgical has integrated digital capabilities providing connected offerings that streamline performance for hospitals with program-enhancing insights.


The company was founded in 1995 and is headquartered in Sunnyvale, California.

Currently out of the existing stock ratings of REGN, 48 are a HOLD (36.09%), 83 are a BUY (62.41%), 2 are a SELL (1.5%).

Analyst name


Current price target

Potential Upside

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$110.89 (10.67%)


2 days ago

2/3 (66.67%)

$104.63 (10.01%)




$189.89 (18.27%)


7 days ago

11/17 (64.71%)

$201.33 (19.59%)




$110.89 (10.67%)


1 months 5 days ago

1/2 (50%)

$165.36 (16.79%)




$-9.11 (-0.88%)


1 months 26 days ago

10/10 (100%)

$123.46 (13.62%)




$59.89 (5.76%)


2 months 2 days ago

4/5 (80%)

$197.81 (21.95%)


Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is REGN (Regeneron Pharmaceuticals) average time for price targets to be met?

On average it took 262.56 days on average for the stock forecasts to be realized with a an average price target met ratio 93.99

Which analyst has the current highest performing score on REGN (Regeneron Pharmaceuticals) with a proven track record?


Which analyst has the most public recommendations on REGN (Regeneron Pharmaceuticals)?

Salveen Richter works at GOLDMAN SACHS and has 5 price targets and 4 ratings on REGN

Which analyst is the currently most bullish on REGN (Regeneron Pharmaceuticals)?

Brian Abrahams with highest potential upside - $189.89

Which analyst is the currently most reserved on REGN (Regeneron Pharmaceuticals)?

Joseph Pantginis with lowest potential downside - -$519.11

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?